克鲁佩尔样因子3 (KLF3) 在清细胞细胞癌中的分子表达和预后影响
Bin Wan1, Wensheng Zhang1, Xinxi Deng1
1Department of Urology, The First People's Hospital of Jiujiang in Jiangxi Province, Jiujiang City, 332000, Jiangxi Province, China.
Critical reviews in eukaryotic gene expression
|December 11, 2023
概括
克鲁佩尔样因子3 (KLF3) 在清细胞细胞癌 (ccRCC) 中显著下调,与预后不佳相关. KLF3可以作为ccRCC患者预后和治疗决策的生物标志物.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 清细胞细胞癌 (ccRCC) 是一种主要的癌亚型.
- 克鲁佩尔样因子3 (KLF3) 功能障碍与各种癌症的预后不佳有关,但其在ccRCC中的作用尚不清楚.
研究的目的:
- 在ccRCC中调查KLF3基因和蛋白质表达.
- 探索KLF3表达与临床病理特征,表观遗传修饰和瘤免疫微环境的相关性.
- 评估KLF3作为ccRCC中的治疗生物标志物的潜力.
主要方法:
- 使用TCGA,HPA,CPTAC和患者队列对KLF3表达的分析.
- 调查KLF3表达与临床病理学参数,甲基化和免疫特征之间的相关性.
- 使用GDSC数据库评估基于KLF3表达的药物敏感性.
主要成果:
- 与正常对照组相比,ccRCC组织中的KLF3显著下调.
- 较低的KLF3表达与不良的病理参数和更差的预后相关.
- KLF3表达与EMT,血管生成,炎症,亡,TGF-β,ECM降解,G2M检查点和PI3K-AKT-mTOR通路有关.
- KLF3的上调与对PI3K-Akt-mTOR抑制剂的敏感性有关,而KLF3的下调表明对Trametinib,Cetuximab和Erlotinib的敏感性.
结论:
- 在ccRCC中,KLF3作为潜在的预后生物标志物.
- KLF3表达可以告知瘤微环境的表型识别.
- KLF3状态可能有助于优化ccRCC患者的治疗策略.
相关概念视频
02:23Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
03:03mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K